<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02449902</url>
  </required_header>
  <id_info>
    <org_study_id>TXV13-01</org_study_id>
    <nct_id>NCT02449902</nct_id>
  </id_info>
  <brief_title>TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of TX-12-004-HR in Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy (VVA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TherapeuticsMD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TherapeuticsMD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was designed to evaluate the efficacy and safety of TX-12-004-HR 10 μg in treating
      moderate to severe symptoms of vaginal atrophy associated with menopause after 14 days of
      treatment, and to estimate the effect size and variability of vulvovaginal atrophy endpoints.
      In addition, the systemic exposure to estradiol from single and multiple doses of
      TX-12-004-HR was to be investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a randomized, double-blind, placebo-controlled trial to evaluate safety and
      efficacy of the TX-12-004-HR formulation in reducing moderate to severe symptoms of vaginal
      atrophy associated with menopause and to investigate the systemic exposure to estradiol
      following once daily intravaginal administrations of TX-12-004-HR for 14 days.

      Postmenopausal subjects who met the study entry criteria were randomized to one of two
      treatment groups (TX-12-004-HR or Placebo). During the Screening period subjects were asked
      to self-assess the symptoms of vulvar and/or vaginal atrophy, including vaginal dryness,
      vaginal and/or vulvar irritation/itching, dysuria, vaginal pain associated with sexual
      activity and vaginal bleeding associated with sexual activity. Subjects with at least one
      self-assessed moderate to severe symptom of vulvar and/or vaginal atrophy identified by the
      subject as being most bothersome to her were eligible to participate in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Parabasal Cells)</measure>
    <time_frame>Baseline to 15 days post-treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Superficial Cells)</measure>
    <time_frame>Baseline to 15 days post-treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Intermediate Cells)</measure>
    <time_frame>Baseline to 15 days post-treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of Change From Baseline to Day 15 in Vaginal pH</measure>
    <time_frame>Baseline to 15 days post-treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of Change From Baseline to Day 15 in Severity of the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom</measure>
    <time_frame>Baseline to 15 days post-treatment</time_frame>
    <description>The severity of the most bothersome VVA symptom was self-assessed by each subject using a VVA questionnaire. The questionnaire has a 4-point scoring scale with: None=0, Mild=1, Moderate=2, and Severe=3. The lower the score, the least bothersome it is to the subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of Change From Baseline to Day 15 in Vaginal Bleeding Associated With Sexual Activity</measure>
    <time_frame>Baseline to 15 days post-treatment</time_frame>
    <description>Total number (N=10) of participants analyzed within each treatment group who were sexually active at both Baseline and Day 15 and provided a response at both visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Color)</measure>
    <time_frame>Baseline to 15 days post-treatment</time_frame>
    <description>Outcome was measured by using a severity scale. No Atrophy is pink in color (0). Mild atrophy is lighter in color (1). Moderate atrophy is pale in color (2). Severe atrophy is transparent, either no color or inflamed (3).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Integrity)</measure>
    <time_frame>Baseline to 15 days post-treatment</time_frame>
    <description>Outcome was measured by using a severity scale. No Atrophy=normal(0). Mild atrophy=vaginal surface bleeds with scraping(1). Moderate atrophy=vaginal surface bleeds with light contact(2). Severe atrophy=vaginal surface has petechiae before contact and bleeds with light contact(3).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Surface Thickness)</measure>
    <time_frame>Baseline to 15 days post-treatment</time_frame>
    <description>Outcome was measured by using a severity scale. No Atrophy has rogation and elasticity of vault(0). Mild atrophy has poor rogation with some elasticity noted of vaginal vault(1). Moderate atrophy is smooth, some elasticity of vaginal vault(2). Severe atrophy is smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)(3).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Secretions)</measure>
    <time_frame>Baseline to 15 days post-treatment</time_frame>
    <description>Outcome was measured by using a severity scale. No Atrophy has normal clear secretions noted on vaginal walls(0). Mild atrophy has superficial coating of secretions, difficulty with speculum insertion(1). Moderate atrophy is scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain(2). Severe atrophy has none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain(3).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Menopause</condition>
  <condition>Vulvovaginal Atrophy</condition>
  <condition>Painful Intercourse</condition>
  <condition>Dyspareunia</condition>
  <arm_group>
    <arm_group_label>Treatment 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Estradiol 10 μg vaginal softgel capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo vaginal softgel capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>1 10 µg capsule inserted vaginally for 14 days.</description>
    <arm_group_label>Treatment 1</arm_group_label>
    <other_name>17β-estradiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1 placebo capsule inserted vaginally for 14 days.</description>
    <arm_group_label>Treatment 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be a female between 40 and 75 years (at the time of randomization) who is willing to
             participate in the study, as documented by signing the informed consent form.

          2. Be a postmenopausal woman. Postmenopausal is defined with at least 12 months of
             spontaneous amenorrhea or 12 months post bilateral oophorectomy, with or without
             hysterectomy (documented by an operative report or patient reported). Women ≥ 60 years
             of age who have had a hysterectomy without bilateral oophorectomy prior to natural
             menopause are considered menopausal.

          3. Have a baseline evaluation requirements:

               -  ≤5% superficial cells on vaginal smear cytology

               -  Vaginal pH &gt; 5.0

               -  Estradiol level ≤ 50 pg/ml

               -  At least one self-assessed moderate to severe symptom of vulvar and/or vaginal
                  atrophy from the following list that is identified by the subject as being most
                  bothersome to her:

                    -  Vaginal dryness

                    -  Vaginal pain associated with sexual activity

                    -  Vaginal and/or vulvar irritation/itching

                    -  Dysuria

                    -  Vaginal bleeding associated with sexual activity (absence vs. presence)

          4. Have a Body Mass Index (BMI) less than or equal to 34 kg/m2. (BMI values should be
             rounded to the nearest integer [e.g., 34.4 rounds down to 34, while 26.5 rounds up to
             27]).

          5. Be willing to abstain from using products (other than study medication) that contain
             estrogen throughout study participation.

          6. Be judged by the Principal Investigator or Sub-investigator as being in otherwise
             generally good health based on a pre-study medical evaluation performed within 28 days
             prior to the initial dose of study medication. The medical evaluation findings must
             include:

               -  a normal or non-clinically significant physical examination, including vital
                  signs (sitting blood pressure, heart rate, respiratory rate and temperature).

               -  a normal or non-clinically significant pelvic examination.

               -  a mammogram that shows no sign of significant disease (can be performed within
                  previous 9 months prior to initial dose of study medication). An acceptable
                  mammogram is defined as a mammogram in which no masses or other findings are
                  identified that is suspicious of malignancy. The site must obtain a copy of the
                  official report for the subject's study file, and it must be verified that the
                  mammogram itself is available if needed for additional assessment.

               -  a normal or non-clinically significant clinical breast examination. An acceptable
                  breast examination is defined as no masses or other findings identified that are
                  suspicious of malignancy.

               -  a normal Screening Papanicolaou (&quot;Pap&quot;) smear (ASCUS with high risk- human
                  papillomavirus (HPV) negative is acceptable).

               -  within normal limits or non-clinically significant laboratory evaluation results

               -  sitting systolic blood pressure ≤140 mmHg and diastolic blood pressure ≤90 mmHg
                  at Screening. A subject may be taking up to two antihypertensive medications.

          7. Be willing to abstain from sexual activity and use of vaginal douching within 24 hours
             prior to screening and Visit 3 vaginal pH measurements.

        Exclusion Criteria:

          1. Be currently hospitalized.

          2. Have a history of thrombosis of deep veins or arteries or a thromboembolic disorder.

          3. Have a history of coronary artery or cerebrovascular disease.

          4. Have a history of liver or kidney dysfunction/disorder.

          5. Have a history of gallbladder dysfunction/disorders (e.g., cholangitis,
             cholecystitis), unless gallbladder has been removed.

          6. Have a history of diabetes, thyroid disease (subjects with diet-controlled diabetes,
             or controlled hypothyroid disease at Screening are not excluded), or any other
             endocrinological disease.

          7. Have a history of estrogen-dependent neoplasia.

          8. Have a history of atypical ductal hyperplasia of the breast.

          9. Have a history of undiagnosed vaginal bleeding.

         10. Have a vaginal infection requiring treatment

         11. Have any history of endometrial hyperplasia or uterine/endometrial, breast or ovarian
             cancer.

         12. Have any history of other malignancy within the last 5 years, with the exception of
             basal cell (excluded if within 1 year) or non-invasive squamous cell (excluded if
             within 1 year) carcinoma of the skin.

         13. Have a history of any other cardiovascular, hepatic, renal, pulmonary, hematologic,
             gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychological, or
             musculoskeletal disease or disorder that is clinically significant in the opinion of
             the Principal Investigator or Medical Sub-Investigator.

         14. Have contraindication to estrogen therapy or allergy to the use of estradiol or any
             components of the investigational drugs.

         15. Use 15 or more cigarettes per day.

         16. Have a history of drug and/or alcohol abuse within one year of start of study.

         17. Have used, within 28 days prior to Screening, or plan to use during the study, any
             prescription or over-the-counter (OTC) medications (including herbal products) that
             would be expected to interact with estradiol therapy.

         18. Use of any type of vaginal preparation (including lubricants and moisturizers) within
             14 days prior to Screening.

         19. Have used estrogen alone or estrogen/progestin for any of the following time periods:

               -  Vaginal hormonal products (rings, creams, gels) within 3 months prior to
                  Screening.

               -  Transdermal estrogen alone or estrogen/progestin products within 8 weeks prior to
                  Screening.

               -  Oral estrogen and/or progestin therapy within 8 weeks prior to Screening.

               -  Progestational implants, estrogen or estrogen/progestational injectable drug
                  therapy within 3 months prior to Screening.

               -  Estrogen pellet therapy or progestational injectable drug therapy within 6 months
                  prior to Screening.

               -  Percutaneous estrogen lotions/gels within 8 weeks prior to Screening.

               -  Oral, topical, vaginal, patch, implantable or injectable androgen therapy within
                  8 weeks prior to Screening.

         20. Have any reason which, in the opinion of the Principal Investigator or Medical
             Sub-Investigator, would prevent the subject from safely participating in the study or
             complying with protocol requirements.

         21. Have contraindication to any planned study procedure (e.g., blood collection).

         22. Have participated in another clinical trial within 30 days prior to screening, have
             received an investigational drug within the three months prior to the initial dose of
             study medication, or be likely to participate in a clinical trial or receive another
             investigational medication during the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shelli Graham, PhD</last_name>
    <role>Study Director</role>
    <affiliation>TherapeuticsMD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avail Clinical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>May 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2015</study_first_posted>
  <results_first_submitted>July 23, 2015</results_first_submitted>
  <results_first_submitted_qc>November 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 14, 2015</results_first_posted>
  <last_update_submitted>November 5, 2015</last_update_submitted>
  <last_update_submitted_qc>November 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VVA</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>Painful Sex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Dyspareunia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TX-12-004-HR 10μg</title>
          <description>Active treatment group. Subjects self-administered the active treatment, a single capsule of 10 μg Estradiol, intravaginally once daily for 14 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Control treatment group. Subjects self-administered the control treatment, a single placebo matching capsule, intravaginally once daily for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Estradiol 10 μg Daily for 14 Days</title>
          <description>Active treatment group. Subjects self-administered the active treatment, a single capsule of 10 μg Estradiol, intravaginally once daily for 14 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Daily for 14 Days</title>
          <description>Control treatment group. Subjects self-administered the control treatment, a single placebo matching capsule, intravaginally once daily for 14 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="5.7"/>
                    <measurement group_id="B2" value="62.3" spread="7.0"/>
                    <measurement group_id="B3" value="62.3" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.4" spread="3.9"/>
                    <measurement group_id="B2" value="27.2" spread="3.3"/>
                    <measurement group_id="B3" value="26.8" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Parabasal Cells)</title>
        <time_frame>Baseline to 15 days post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TX-12-004-HR 10μg</title>
            <description>Active treatment group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control treatment group.</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Parabasal Cells)</title>
          <units>Percentage of Parabasal Cells</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.4" spread="4.6"/>
                    <measurement group_id="O2" value="-4.8" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Superficial Cells)</title>
        <time_frame>Baseline to 15 days post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TX-12-004-HR 10μg</title>
            <description>Active treatment group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control treatment group.</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Superficial Cells)</title>
          <units>Percentage of Superficial Cells</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2" spread="4.7"/>
                    <measurement group_id="O2" value="8.8" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Intermediate Cells)</title>
        <time_frame>Baseline to 15 days post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TX-12-004-HR 10μg</title>
            <description>Active treatment group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control treatment group.</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Intermediate Cells)</title>
          <units>Percentage of Intermediate Cells</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="4.7"/>
                    <measurement group_id="O2" value="-3.5" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0017</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Analysis of Change From Baseline to Day 15 in Vaginal pH</title>
        <time_frame>Baseline to 15 days post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TX-12-004-HR 10μg</title>
            <description>Active treatment group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control treatment group.</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Change From Baseline to Day 15 in Vaginal pH</title>
          <units>pH</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="0.1"/>
                    <measurement group_id="O2" value="-0.34" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Analysis of Change From Baseline to Day 15 in Severity of the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom</title>
        <description>The severity of the most bothersome VVA symptom was self-assessed by each subject using a VVA questionnaire. The questionnaire has a 4-point scoring scale with: None=0, Mild=1, Moderate=2, and Severe=3. The lower the score, the least bothersome it is to the subject.</description>
        <time_frame>Baseline to 15 days post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TX-12-004-HR 10μg</title>
            <description>Active treatment group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control treatment group.</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Change From Baseline to Day 15 in Severity of the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom</title>
          <description>The severity of the most bothersome VVA symptom was self-assessed by each subject using a VVA questionnaire. The questionnaire has a 4-point scoring scale with: None=0, Mild=1, Moderate=2, and Severe=3. The lower the score, the least bothersome it is to the subject.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.043" spread="0.2"/>
                    <measurement group_id="O2" value="-1.042" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9951</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Analysis of Change From Baseline to Day 15 in Vaginal Bleeding Associated With Sexual Activity</title>
        <description>Total number (N=10) of participants analyzed within each treatment group who were sexually active at both Baseline and Day 15 and provided a response at both visits.</description>
        <time_frame>Baseline to 15 days post-treatment</time_frame>
        <population>Total number (N=10) of participants analyzed within each treatment group who were sexually active at both Baseline and Day 15 and provided a response at both visits.</population>
        <group_list>
          <group group_id="O1">
            <title>TX-12-004-HR 10μg</title>
            <description>Active treatment group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control treatment group.</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Change From Baseline to Day 15 in Vaginal Bleeding Associated With Sexual Activity</title>
          <description>Total number (N=10) of participants analyzed within each treatment group who were sexually active at both Baseline and Day 15 and provided a response at both visits.</description>
          <population>Total number (N=10) of participants analyzed within each treatment group who were sexually active at both Baseline and Day 15 and provided a response at both visits.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bleeding/ No Bleeding (Success)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding/ Bleeding (Failure)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Bleeding/ Bleeding (Failure)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Bleeding/ No Bleeding (No Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1429</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Color)</title>
        <description>Outcome was measured by using a severity scale. No Atrophy is pink in color (0). Mild atrophy is lighter in color (1). Moderate atrophy is pale in color (2). Severe atrophy is transparent, either no color or inflamed (3).</description>
        <time_frame>Baseline to 15 days post-treatment</time_frame>
        <population>All participants receiving at least one day of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>TX-12-004-HR 10μg</title>
            <description>Active treatment group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control treatment group.</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Color)</title>
          <description>Outcome was measured by using a severity scale. No Atrophy is pink in color (0). Mild atrophy is lighter in color (1). Moderate atrophy is pale in color (2). Severe atrophy is transparent, either no color or inflamed (3).</description>
          <population>All participants receiving at least one day of study medication.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.199" spread="0.1"/>
                    <measurement group_id="O2" value="-0.009" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1945</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Integrity)</title>
        <description>Outcome was measured by using a severity scale. No Atrophy=normal(0). Mild atrophy=vaginal surface bleeds with scraping(1). Moderate atrophy=vaginal surface bleeds with light contact(2). Severe atrophy=vaginal surface has petechiae before contact and bleeds with light contact(3).</description>
        <time_frame>Baseline to 15 days post-treatment</time_frame>
        <population>All participants receiving at least one day of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>TX-12-004-HR 10μg</title>
            <description>Active treatment group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control treatment group.</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Integrity)</title>
          <description>Outcome was measured by using a severity scale. No Atrophy=normal(0). Mild atrophy=vaginal surface bleeds with scraping(1). Moderate atrophy=vaginal surface bleeds with light contact(2). Severe atrophy=vaginal surface has petechiae before contact and bleeds with light contact(3).</description>
          <population>All participants receiving at least one day of study medication.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.342" spread="0.1"/>
                    <measurement group_id="O2" value="0.176" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Surface Thickness)</title>
        <description>Outcome was measured by using a severity scale. No Atrophy has rogation and elasticity of vault(0). Mild atrophy has poor rogation with some elasticity noted of vaginal vault(1). Moderate atrophy is smooth, some elasticity of vaginal vault(2). Severe atrophy is smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)(3).</description>
        <time_frame>Baseline to 15 days post-treatment</time_frame>
        <population>All participants receiving at least one day of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1</title>
            <description>Estradiol 10 μg vaginal softgel capsule
Estradiol: 1 10 µg capsule inserted vaginally for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2</title>
            <description>Placebo vaginal softgel capsule
placebo: 1 placebo capsule inserted vaginally for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Surface Thickness)</title>
          <description>Outcome was measured by using a severity scale. No Atrophy has rogation and elasticity of vault(0). Mild atrophy has poor rogation with some elasticity noted of vaginal vault(1). Moderate atrophy is smooth, some elasticity of vaginal vault(2). Severe atrophy is smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)(3).</description>
          <population>All participants receiving at least one day of study medication.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.034" spread="0.1"/>
                    <measurement group_id="O2" value="-0.133" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1820</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Secretions)</title>
        <description>Outcome was measured by using a severity scale. No Atrophy has normal clear secretions noted on vaginal walls(0). Mild atrophy has superficial coating of secretions, difficulty with speculum insertion(1). Moderate atrophy is scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain(2). Severe atrophy has none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain(3).</description>
        <time_frame>Baseline to 15 days post-treatment</time_frame>
        <population>All participants receiving at least one day of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>TX-12-004-HR 10μg</title>
            <description>Active treatment group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control treatment group.</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Secretions)</title>
          <description>Outcome was measured by using a severity scale. No Atrophy has normal clear secretions noted on vaginal walls(0). Mild atrophy has superficial coating of secretions, difficulty with speculum insertion(1). Moderate atrophy is scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain(2). Severe atrophy has none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain(3).</description>
          <population>All participants receiving at least one day of study medication.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.643" spread="0.1"/>
                    <measurement group_id="O2" value="-0.274" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0401</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for 14 days (study duration). Subjects with AEs that were ongoing at study completion or study withdrawal were followed until resolution or for 30 days after the last dose of study medication.</time_frame>
      <desc>Investigators evaluated adverse events for duration, severity, seriousness, causal relationship to the investigational drug and reviewed laboratory assessments per protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>TX-12-004-HR</title>
          <description>Active treatment group.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Control treatment group.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vulvovaginal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vulvovaginal burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators may publish their own data provided that the information is reviewed by the Sponsor. Otherwise, publication of the outcome and results of the study will be the sole domain of Sponsor, and publication of the study results by the Institution or Principal Investigator is not permitted, except with the Sponsor’s prior written consent.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shelli Graham, PhD</name_or_title>
      <organization>TherapeuticsMD</organization>
      <phone>561-961-1900</phone>
      <email>Shelli.Graham@TherapeuticsMD.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

